Share Price and Basic Stock Data
Last Updated: September 3, 2024, 11:03 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ortin Laboratories Ltd operates in the pharmaceuticals sector, with a reported market capitalization of ₹16.4 Cr and a share price standing at ₹20.1. The company has experienced significant fluctuations in revenue over the past few years. Sales reported in the fiscal year ending March 2024 stood at ₹2.28 Cr, a steep decline from ₹6.00 Cr in March 2023 and ₹8.23 Cr in March 2022. This downward trend is particularly concerning when compared to historical performance, with sales peaking at ₹197.36 Cr in March 2020. Quarterly sales have also shown volatility, with the latest report for September 2023 indicating a mere ₹0.27 Cr. The company’s operational challenges are evident in the operating profit margins, which have seen drastic changes, leading to negative profitability figures in recent quarters. The company’s operational struggles raise questions about its market positioning and demand for its products.
Profitability and Efficiency Metrics
Profitability metrics for Ortin Laboratories reveal a troubling trend, with the net profit for the fiscal year ending March 2024 recorded at a loss of ₹8.04 Cr, worsening from a loss of ₹0.09 Cr in March 2023. The operating profit margin (OPM) has been alarmingly negative, reported at -1,016.67% in March 2024, indicating that expenses have far outweighed revenues. Historical data shows a pattern of volatility, with OPM fluctuating between positive and negative values across the previous quarters. The return on equity (ROE) stood at a remarkable 118%, yet this figure may be misleading due to the negative earnings impacting overall profitability. The interest coverage ratio (ICR) was reported at 3.63x, which indicates some capacity to cover interest obligations, but the ongoing losses suggest that the company may struggle to maintain this level of operational efficiency in the future.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ortin Laboratories reflects a precarious financial situation, particularly with reserves showing a negative balance of ₹5.31 Cr as of March 2024. Borrowings stood at ₹1.80 Cr, significantly lower than previous years, suggesting either a reduction in debt or diminished operational scale. The price-to-book value (P/BV) ratio was recorded at 1.97x, indicating that the market values the company slightly higher than its book value, which may not be sustainable given the recent financial performance. The total assets have declined to ₹6.59 Cr from previous highs, signaling a reduction in operational scale and potential liquidity issues. The company’s declining revenues and negative reserves raise concerns about its ability to finance growth or reinvest in operations, which may further hinder recovery efforts.
Shareholding Pattern and Investor Confidence
The shareholding pattern for Ortin Laboratories indicates a lack of transparency, with no available data on promoters, FIIs, DIIs, or public shareholders. This absence of information may contribute to investor uncertainty, especially in light of the company’s poor financial performance. The market’s reaction to Ortin’s declining revenues and profitability suggests a lack of confidence among potential investors. The company’s high P/E ratio, while not explicitly stated, could indicate that the market is pricing in future growth potential that is currently unsubstantiated by performance metrics. The absence of institutional backing or significant public shareholding typically raises red flags, as it may point to a lack of trust in the company’s management and operational strategy.
Outlook, Risks, and Final Insight
The outlook for Ortin Laboratories appears challenging, primarily due to its declining revenue streams and increasing operational losses. The significant drop in sales and negative profitability metrics indicate that the company must undertake substantial strategic changes to regain investor confidence and operational viability. Key risks include the company’s ability to manage ongoing losses and the potential for further declines in revenue, which could lead to liquidity issues. Additionally, the negative reserves suggest that the company may face difficulties in financing growth or covering operational costs. For Ortin Laboratories to improve its standing, strategic initiatives focusing on cost management, operational efficiency, and market repositioning will be crucial. If successful, the company could potentially return to profitability; however, failure to address these issues may result in continued financial distress and loss of market presence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,407 Cr. | 404 | 479/192 | 91.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,548.27 Cr | 1,144.26 | 53.57 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.76 | 1.98 | 2.29 | 1.66 | 2.45 | 2.62 | 0.79 | 1.17 | 1.49 | 1.57 | 0.27 | 0.14 | 0.30 |
| Expenses | 1.55 | 1.61 | 2.00 | 1.65 | 2.59 | 2.41 | 1.01 | 0.55 | 1.52 | 1.39 | 1.17 | 2.74 | 3.35 |
| Operating Profit | 0.21 | 0.37 | 0.29 | 0.01 | -0.14 | 0.21 | -0.22 | 0.62 | -0.03 | 0.18 | -0.90 | -2.60 | -3.05 |
| OPM % | 11.93% | 18.69% | 12.66% | 0.60% | -5.71% | 8.02% | -27.85% | 52.99% | -2.01% | 11.46% | -333.33% | -1,857.14% | -1,016.67% |
| Other Income | 0.05 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.19 | 0.18 | 0.19 | 0.19 | 0.24 | 0.10 | 0.09 | 0.10 | 0.12 | 0.11 | 0.15 | 0.14 | 0.08 |
| Depreciation | 0.07 | 0.07 | 0.07 | -0.07 | 0.23 | 0.07 | 0.07 | 0.07 | 0.03 | 0.06 | 0.06 | 0.06 | 0.05 |
| Profit before tax | 0.00 | 0.12 | 0.07 | -0.11 | -0.61 | 0.04 | -0.38 | 0.45 | -0.21 | 0.01 | -1.11 | -2.80 | -3.18 |
| Tax % | 25.00% | 28.57% | -18.18% | -24.59% | 1,150.00% | -121.05% | 0.00% | -4.76% | 0.00% | 1.80% | -0.71% | 30.19% | |
| Net Profit | 0.80 | 0.09 | 0.05 | -0.09 | -0.45 | -0.43 | 0.08 | 0.46 | -0.20 | 0.02 | -1.12 | -2.79 | -4.14 |
| EPS in Rs | 0.98 | 0.11 | 0.06 | -0.11 | -0.55 | -0.53 | 0.10 | 0.57 | -0.25 | 0.02 | -1.38 | -3.43 | -5.09 |
Last Updated: Unknown
Below is a detailed analysis of the quarterly data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Sales, as of Mar 2024, the value is 0.30 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Dec 2023) to 0.30 Cr., marking an increase of 0.16 Cr..
- For Expenses, as of Mar 2024, the value is 3.35 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.74 Cr. (Dec 2023) to 3.35 Cr., marking an increase of 0.61 Cr..
- For Operating Profit, as of Mar 2024, the value is -3.05 Cr.. The value appears to be declining and may need further review. It has decreased from -2.60 Cr. (Dec 2023) to -3.05 Cr., marking a decrease of 0.45 Cr..
- For OPM %, as of Mar 2024, the value is -1,016.67%. The value appears strong and on an upward trend. It has increased from -1,857.14% (Dec 2023) to -1,016.67%, marking an increase of 840.47%.
- For Other Income, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded 0.00 Cr..
- For Interest, as of Mar 2024, the value is 0.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.14 Cr. (Dec 2023) to 0.08 Cr., marking a decrease of 0.06 Cr..
- For Depreciation, as of Mar 2024, the value is 0.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Dec 2023) to 0.05 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Mar 2024, the value is -3.18 Cr.. The value appears to be declining and may need further review. It has decreased from -2.80 Cr. (Dec 2023) to -3.18 Cr., marking a decrease of 0.38 Cr..
- For Tax %, as of Mar 2024, the value is 30.19%. The value appears to be increasing, which may not be favorable. It has increased from -0.71% (Dec 2023) to 30.19%, marking an increase of 30.90%.
- For Net Profit, as of Mar 2024, the value is -4.14 Cr.. The value appears to be declining and may need further review. It has decreased from -2.79 Cr. (Dec 2023) to -4.14 Cr., marking a decrease of 1.35 Cr..
- For EPS in Rs, as of Mar 2024, the value is -5.09. The value appears to be declining and may need further review. It has decreased from -3.43 (Dec 2023) to -5.09, marking a decrease of 1.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: Unknown
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.74 | 67.00 | 60.29 | 62.72 | 61.57 | 79.63 | 167.51 | 197.36 | 8.16 | 8.23 | 6.00 | 2.28 |
| Expenses | 68.17 | 60.90 | 53.80 | 56.83 | 56.12 | 74.22 | 160.83 | 191.66 | 6.92 | 7.85 | 5.47 | 8.65 |
| Operating Profit | 6.57 | 6.10 | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.70 | 1.24 | 0.38 | 0.53 | -6.37 |
| OPM % | 8.79% | 9.10% | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.20% | 4.62% | 8.83% | -279.39% |
| Other Income | 0.24 | 0.81 | 0.00 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | 0.00 |
| Interest | 3.55 | 3.72 | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.40 | 0.48 |
| Depreciation | 1.40 | 1.51 | 1.64 | 1.65 | 1.70 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 |
| Profit before tax | 1.86 | 1.68 | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | -0.53 | -0.11 | -7.08 |
| Tax % | 41.40% | 29.17% | 32.33% | 41.01% | 55.75% | 0.00% | 30.43% | 181.69% | -623.08% | -24.53% | -18.18% | 13.56% |
| Net Profit | 1.09 | 1.19 | 0.90 | 0.83 | 0.50 | 0.68 | 1.28 | -0.56 | 0.95 | -0.40 | -0.09 | -8.04 |
| EPS in Rs | 0.64 | 0.70 | 0.53 | 0.49 | 0.30 | 0.40 | 0.76 | -0.33 | 1.17 | -0.49 | -0.11 | -9.89 |
| Dividend Payout % | 38.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.17% | -24.37% | -7.78% | -39.76% | 36.00% | 88.24% | -143.75% | 269.64% | -142.11% | 77.50% | -8833.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -33.54% | 16.59% | -31.98% | 75.76% | 52.24% | -231.99% | 413.39% | -411.75% | 219.61% | -8910.83% |
Ortin Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: Unknown
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 |
| Reserves | 3.84 | 5.02 | 5.50 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | -5.31 |
| Borrowings | 17.92 | 18.68 | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.80 |
| Other Liabilities | 34.80 | 31.93 | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 1.97 |
| Total Liabilities | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
| Fixed Assets | 24.77 | 23.90 | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.40 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0.00 |
| Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 48.70 | 48.64 | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.58 |
| Total Assets | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
Below is a detailed analysis of the balance sheet data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2024, the value is 8.13 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 8.13 Cr..
- For Reserves, as of Mar 2024, the value is -5.31 Cr.. The value appears to be declining and may need further review. It has decreased from 2.73 Cr. (Mar 2023) to -5.31 Cr., marking a decrease of 8.04 Cr..
- For Borrowings, as of Mar 2024, the value is 1.80 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 6.45 Cr. (Mar 2023) to 1.80 Cr., marking a decrease of 4.65 Cr..
- For Other Liabilities, as of Mar 2024, the value is 1.97 Cr.. The value appears to be improving (decreasing). It has decreased from 3.89 Cr. (Mar 2023) to 1.97 Cr., marking a decrease of 1.92 Cr..
- For Total Liabilities, as of Mar 2024, the value is 6.59 Cr.. The value appears to be improving (decreasing). It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
- For Fixed Assets, as of Mar 2024, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 13.96 Cr. (Mar 2023) to 0.01 Cr., marking a decrease of 13.95 Cr..
- For CWIP, as of Mar 2024, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.43 Cr. (Mar 2023) to 0.00 Cr., marking a decrease of 0.43 Cr..
- For Investments, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2024, the value is 6.58 Cr.. The value appears to be declining and may need further review. It has decreased from 6.81 Cr. (Mar 2023) to 6.58 Cr., marking a decrease of 0.23 Cr..
- For Total Assets, as of Mar 2024, the value is 6.59 Cr.. The value appears to be declining and may need further review. It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
However, the Borrowings (1.80 Cr.) are higher than the Reserves (-5.31 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -11.35 | -12.58 | -14.47 | -14.96 | -11.89 | -11.93 | -12.79 | -13.87 | -5.70 | -5.76 | -5.92 | -8.17 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
No data available for the Shareholding
No data available for the Shareholding Pattern chart.
No data available for the No. of Shareholders chart.
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 12 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 2.73 |
| Diluted EPS (Rs.) | 2.73 |
| Cash EPS (Rs.) | 3.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.47 |
| Revenue From Operations / Share (Rs.) | 50.63 |
| PBDIT / Share (Rs.) | 6.99 |
| PBIT / Share (Rs.) | 6.13 |
| PBT / Share (Rs.) | 4.20 |
| Net Profit / Share (Rs.) | 2.73 |
| NP After MI And SOA / Share (Rs.) | 2.73 |
| PBDIT Margin (%) | 13.81 |
| PBIT Margin (%) | 12.10 |
| PBT Margin (%) | 8.30 |
| Net Profit Margin (%) | 5.38 |
| NP After MI And SOA Margin (%) | 5.38 |
| Return on Networth / Equity (%) | 18.85 |
| Return on Capital Employeed (%) | 34.77 |
| Return On Assets (%) | 5.67 |
| Long Term Debt / Equity (X) | 0.11 |
| Total Debt / Equity (X) | 0.58 |
| Current Ratio (X) | 1.11 |
| Quick Ratio (X) | 0.82 |
| Interest Coverage Ratio (X) | 3.63 |
| Interest Coverage Ratio (Post Tax) (X) | 2.42 |
| Enterprise Value (Cr.) | 62.39 |
| EV / Net Operating Revenue (X) | 0.72 |
| EV / EBITDA (X) | 5.27 |
| MarketCap / Net Operating Revenue (X) | 0.56 |
| Price / BV (X) | 1.97 |
| Price / Net Operating Revenue (X) | 0.56 |
| EarningsYield | 0.09 |
After reviewing the key financial ratios for Ortin Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 12, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 12, the value is 3.59. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 12, the value is 50.63. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 12, the value is 6.99. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 12, the value is 6.13. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 12, the value is 4.20. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 12, the value is 13.81. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 12, the value is 12.10. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 12, the value is 8.30. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 12, the value is 5.38. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 12, the value is 5.38. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 12, the value is 18.85. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 12, the value is 34.77. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 12, the value is 5.67. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 12, the value is 0.11. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 12, the value is 0.58. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 12, the value is 1.11. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 12, the value is 0.82. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 12, the value is 3.63. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 12, the value is 2.42. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 12, the value is 62.39. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 12, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 12, the value is 5.27. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 12, the value is 1.97. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 12, the value is 0.09. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ortin Laboratories Ltd:
- Net Profit Margin: 5.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 34.77% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.85% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.57)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.58
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | D. No. 1-8-B4, Ground Floor, F3 HIG, Block-4, Street No.3, Hyderabad Telangana 500044 | info@ortinlabsindia.com http://www.ortinlabsindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murali Krishna Rayaprolu | Chairman & Ind.Director |
| Mr. S Murali Krishna Murthy | Managing Director |
| Mr. S Srinivas Kumar | Whole Time Director |
| Mr. S Balaji Venkateswarlu | Non Executive Director |
| Mr. B Gopal Reddy | Independent Director |
| Ms. Pottur Sujatha | Independent Director |
Ortin Laboratories Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹18.00 |
| Previous Day | ₹18.48 |
FAQ
What is the intrinsic value of Ortin Laboratories Ltd?
Ortin Laboratories Ltd's intrinsic value (as of 04 December 2025) is 50.12 which is 149.35% higher the current market price of 20.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 16.4 Cr. market cap, FY2025-2026 high/low of 26.4/16.2, reserves of ₹-5.31 Cr, and liabilities of 6.59 Cr.
What is the Market Cap of Ortin Laboratories Ltd?
The Market Cap of Ortin Laboratories Ltd is 16.4 Cr..
What is the current Stock Price of Ortin Laboratories Ltd as on 04 December 2025?
The current stock price of Ortin Laboratories Ltd as on 04 December 2025 is 20.1.
What is the High / Low of Ortin Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ortin Laboratories Ltd stocks is 26.4/16.2.
What is the Stock P/E of Ortin Laboratories Ltd?
The Stock P/E of Ortin Laboratories Ltd is .
What is the Book Value of Ortin Laboratories Ltd?
The Book Value of Ortin Laboratories Ltd is 3.47.
What is the Dividend Yield of Ortin Laboratories Ltd?
The Dividend Yield of Ortin Laboratories Ltd is 0.00 %.
What is the ROCE of Ortin Laboratories Ltd?
The ROCE of Ortin Laboratories Ltd is 60.2 %.
What is the ROE of Ortin Laboratories Ltd?
The ROE of Ortin Laboratories Ltd is 118 %.
What is the Face Value of Ortin Laboratories Ltd?
The Face Value of Ortin Laboratories Ltd is 10.0.